medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 5

<< Back Next >>

Ann Hepatol 2016; 15 (5)

Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries

Seydel GS, Kucukoglu O, Altinbas A, Demir, OO, Yilmaz, S, Akkiz H, Otan E, Sowa Jan-Peter, Canbay A

Language: English
References: 74
Page: 662-672
PDF size: 194.62 Kb.


ABSTRACT

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the third leading cause of cancer related death worldwide. In recent years, the prevalence of HCC has increased in both developing and developed countries. Most HCC cases develop in the presence of advanced chronic liver disease related to viral hepatitis. In particular hepatitis B virus and hepatitis C virus infections are considered as major HCC risk factors worldwide. However, current studies provide strong evidence for increasing numbers of HCC in nonalcoholic fatty liver disease (NAFLD). NAFLD represents the hepatic manifestation of metabolic syndrome which is based on obesity and insulin resistance. Epidemiologic data clearly demonstrates that NAFLD and obesity-related disorders are significant risk factors for tumor development in general and HCC in particular. As a consequence of life style changes towards higher calorie intake and less exercise, obesity and metabolic syndrome are spreading all over the world. Due to this increase in obesity and metabolic syndrome NAFLD-related HCC will become a major health care problem in the future. In conclusion, better understanding of the impact of NAFLD and obesity in the development of HCC will improve our treatment strategies of HCC and allow preventive measures.


REFERENCES

  1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.

  2. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011; 15: 223-43.

  3. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-91.

  4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

  5. Méndez-Sánchez N, Villa AR, Vázquez-Elizondo G, Ponciano- Rodríguez G, Uribe M. Mortality trends for liver cancer in Mexico from 2000 to 2006. Ann Hepatol 2008; 7: 226-9.

  6. Sakar B, Ustuner Z, Karagol H, Aksu G, Camlica H, Aykan NF. Prognostic features and survival of inoperable hepatocellular carcinoma in Turkish patients with cirrhosis. Am J Clin Oncol 2004; 27: 489-493.

  7. Yalcin K, Yakut M, Degertekin H, Turkdogan K, Harputluoglu M, Bahcecioglu IH, Kadayifi A, et al. Clinical and epidemiological characteristics of hepatocellular carcinoma cases in East and Southeastern Region of Turkey: A Multicenter Retrospective Study. J Med Sci 2013; 33: 806-13.

  8. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-43.

  9. Yaprak O, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y, et al. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2012; 11: 256-61.

  10. Uzunalimoglu O, Yurdaydin C, Cetinkaya H, Bozkaya H, Sahin T, Colakoglu S, Tankurt E, et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001; 46: 1022-8.

  11. Ozer B, Serin E, Yilmaz U, Gumurdulu Y, Saygili OB, Kayaselcuk F, Boyacioðlu S, et al. Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey. Turk J Gastroenterol 2003; 14: 85-90.

  12. Dogan E, Yalcin S, Koca D, Olmez A. Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev 2012; 13: 2985-90.

  13. Can A, Dogan E, Bayoglu IV, Tatli AM, Besiroglu M, Kocer M, Dulger AC, et al. Multicenter epidemiologic study on hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev 2014; 15: 2923-7.

  14. Bassullu N, Turkmen I, Yaprak O, Dayangac M, Demirbas T, Guler N, Uraz S, et al. General evaluation of hepatectomy and hepatocellular carcinoma cases. Turk Patoloji Dergisi 2011; 27: 221-9.

  15. Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, Alkis N, et al. Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol 2008; 38: 683-8.

  16. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010; 51: 679-89.

  17. Asrih M, Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol Cell Endocrinol 2015.

  18. Nader LA, de Mattos AA, Bastos GA. Burden of liver disease in Brazil. Liver Int 2014; 34: 844-9.

  19. Méndez-Sánchez N, Sánchez-Castillo CP, Villa AR, Madrigal H, Merino B, García E, López P, et al. The relationship of overweight and obesity to high mortality rates from liver cirrhosis in Mexico. Ann Hepatol 2004; 3(2): 66-71.

  20. Yumuk VD. Prevalence of obesity in Turkey. Obes Rev 2005; 6: 9-10.

  21. World Health Organisation (WHO): Global Database on Body Mass Index.

  22. Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 2015; 21: 4103-10.

  23. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28: 169-80.

  24. Hatemi H, Turan N, Arik N, Yumuk V. The Turkish obesity and hypertension study (TOHS). Endokrinolojide Yönelisler Dergisi 2002; 11.

  25. Sanisoglu SY, Oktenli C, Hasimi A, Yokusoglu M, Ugurlu M. Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health 2006; 6: 92.

  26. Bagriacik N, Onat H, Ilhan B, Tarakci T, Osar Z, Ozyazar M, Hatemi HH, et al. Obesity profile in Turkey. Int J Diabetes & Metabolism 2009; 17: 5-8.

  27. Onat A, Yidirim B, Cetinkaya A, Aksu H, Sansoy V. Obesity prevelance in Turkey. TEKHARF Arsivi 1999; 27: 209-15.

  28. Iseri A, Arslan N. Obesity in adults in Turkey: age and regional effects. Eur J Public Health 2009; 19: 91-4.

  29. Ozgul N, Tuncer M, Abacioglu M, Gultekin M. Prevalence of obesity among women in Turkey: analysis of KETEM data. Asian Pacific J Cancer Prev 2011; 12: 2401-4.

  30. Devaux M, Sassi F. Social inequalities in obesity and overweight in 11 OECD countries. Eur J Public Health 2013; 23: 464-9.

  31. Dinsa GD, Goryakin Y, Fumagalli E, Suhrcke M. Obesity and socioeconomic status in developing countries: a systematic review. Obes Rev 2012; 13: 1067-79.

  32. Pampel FC, Denney JT, Krueger PM. Obesity, SES, and economic development: a test of the reversal hypothesis. Soc Sci Med 2012; 74: 1073-81.

  33. Kinge JM, Strand BH, Vollset SE, Skirbekk V. Educational inequalities in obesity and gross domestic product: evidence from 70 countries. J Epidemiol Community Health 2015.

  34. Ozer MK, Erman A, Cetin E, Toraman NF. Difference between Urban and Squatter Areas. Asian Journal of Epidemiology 2010: 1-7.

  35. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815-25.

  36. Levy E, Levy P, Le Pen C, Basdevant A. The economic cost of obesity: the French situation. Int J Obes Relat Metab Disord 1995; 19: 788-92.

  37. Colagiuri S, Lee CM, Colagiuri R, Magliano D, Shaw JE, Zimmet PZ, Caterson ID, et al. The cost of overweight and obesity in Australia. Med J Aust 2010; 192: 260-4.

  38. OECD. Health Statistics 2015 Database (http://stats.oecd. org/index.aspx?DataSetCode=HEALTH_STAT).

  39. Butland B, Jebb S, Kopelman P, McPherson K, Thomas S, Mardell J, Parry V, et al. Foresight, “Tackling Obesities: Future Choices-Project Report 2nd Edition. Government Office for Science; 2007.

  40. Bullard KM, Saydah SH, Imperatore G, Cowie CC, Gregg EW, Geiss LS, Cheng YJ, et al. Secular changes in U.S. Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999-2010. Diab Care 2013; 36: 2286-93.

  41. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol 2012; 8: 228-36.

  42. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. JAMA 2015; 314: 1021-9.

  43. Tamayo T, Rosenbauer J, Wild SH, Spijkerman AM, Baan C, Forouhi NG, Herder C, et al. Diabetes in Europe: an update. Diabetes Res Clin Pract 2014; 103: 206-17.

  44. Sozmen K, Unal B, Capewell S, Critchley J, O’Flaherty M. Estimating diabetes prevalence in Turkey in 2025 with and without possible interventions to reduce obesity and smoking prevalence, using a modelling approach. Int J Public Health 2015; 60(Suppl. 1): S13-S21.

  45. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.

  46. O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 2015; 16: 1-12.

  47. Corey KE, Kaplan LM. Obesity and liver disease: the epidemic of the twenty-first century. Clin Liver Dis 2014; 18: 1-18.

  48. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA 2015; 313: 1973-4.

  49. Erem C, Hacihasanoglu A, Deger O, Topbas M, Hosver I, Ersoz HO, Can G. Prevalence of metabolic syndrome and associated risk factors among Turkish adults: Trabzon MetS study. Endocrine 2008; 33: 9-20.

  50. Gundogan K, Bayram F, Capak M, Tanriverdi F, Karaman A, Ozturk A, Altunbas H, et al. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. Metab Syndr Relat Disord 2009; 7: 427-34.

  51. Akbulut G, Koksal E, Bilici S, Acar Tek N, Yildiran H, Karadag MG, Sanlier N. Metabolic syndrome (MS) in elderly: a cross sectional survey. Arch Gerontol Geriatr 2011; 53: e263- e266.

  52. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014; 59: 1174-97.

  53. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion 2011; 83: 124-33.

  54. Chettouh H, Lequoy M, Fartoux L, Vigouroux C, Desbois- Mouthon C. Hyperinsulinaemia and insulin signaling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int 2015; 35: 2203-17.

  55. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, Panagiotakos DB, et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 2013; 44: 634-47.

  56. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009; 101: 48-60.

  57. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.

  58. Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, Das B, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India 2013; 61: 448-53.

  59. Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 2014; 63: 161-7.

  60. Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol 2013; 23: 471-82.

  61. Boyraz M, Hatipoglu N, Sari E, Akcay A, Taskin N, Ulucan K, Akçay T. Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obes Res Clin Pract 2014; 8: e356-e363.

  62. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.

  63. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 2014; 28: 637-53.

  64. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113-9.

  65. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diab Care 2007; 30: 1212-8.

  66. Pirgon O, Bilgin H, Cekmez F, Kurku H, Dundar BN. Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol 2013; 5: 33-9.

  67. Atabek ME, Pirgon O, Kurtoglu S. Prevalence of metabolic syndrome in obese Turkish children and adolescents. Diabetes Res Clin Pract 2006; 72: 315-21.

  68. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Populationbased risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-91.

  69. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-30.

  70. Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, Angus PW. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterology 2015; 21: 1189-96.

  71. Schutte K, Schulz C, Poranzke J, Antweiler K, Bornschein J, Bretschneider T, Arend J, et al. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterology 2014; 14: 117.

  72. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012; 56: 704-13.

  73. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-9.

  74. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.




2020     |     www.medigraphic.com